CRL:NYE-Charles River Laboratories International Inc. (USD)

EQUITY | Diagnostics & Research | New York Stock Exchange

Last Closing

USD 227.81

Change

-11.62 (-4.85)%

Market Cap

USD 3.40B

Volume

0.76M

Analyst Target

USD 238.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Charles River Laboratories International Inc provides research models and services required to enable in vivo drug discovery and development.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-25 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
TMO Thermo Fisher Scientific Inc

N/A

USD 220.96B
DHR Danaher Corporation

N/A

USD 182.08B
IQV IQVIA Holdings Inc

N/A

USD 42.75B
A Agilent Technologies Inc

N/A

USD 40.87B
MTD Mettler-Toledo International I..

N/A

USD 27.82B
WAT Waters Corporation

N/A

USD 19.89B
LH Laboratory Corporation of Amer..

N/A

USD 17.77B
DGX Quest Diagnostics Incorporated

N/A

USD 14.27B
RVTY Revvity Inc.

N/A

USD 12.54B
QGEN Qiagen NV

N/A

USD 9.22B

ETFs Containing CRL

JSMD Janus Henderson Small/Mid.. 2.74 % 0.50 %

N/A

USD 0.34B
HEAL:CA 2.65 % 0.00 %

N/A

N/A
SAEF Schwab Strategic Trust 2.24 % 0.00 %

N/A

USD 0.02B
XMLH:F Legal & General Ucits Etf.. 2.04 % 0.00 %

N/A

USD 0.08B
DOCT:SW L&G Healthcare Breakthrou.. 2.04 % 0.00 %

N/A

USD 0.08B
XLVE:CA Mulvihill U.S. Health Car.. 1.86 % 0.00 %

N/A

CAD 6.58M
DOCG:LSE L&G Healthcare Breakthrou.. 1.81 % 0.00 %

N/A

USD 0.08B
DOCT:LSE L&G Healthcare Breakthrou.. 1.81 % 0.00 %

N/A

USD 0.08B
HEAL:LSE iShares Healthcare Innova.. 1.77 % 0.00 %

N/A

USD 1.07B
HEAL:SW iShares Healthcare Innova.. 1.66 % 0.00 %

N/A

N/A
GNRX 0.00 % 0.55 %

N/A

N/A
FSMD Fidelity Small-Mid Factor 0.00 % 0.00 %

N/A

USD 0.21B
IS3V:XETRA iShares Global Inflation .. 0.00 % 0.00 %

N/A

USD 0.20B
XMLH:XETRA L&G Healthcare Breakthrou.. 0.00 % 0.00 %

N/A

USD 0.07B
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.63% 47% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.63% 47% F 25% F
Trailing 12 Months  
Capital Gain 24.01% 92% A 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.01% 92% A 76% C+
Trailing 5 Years  
Capital Gain 59.61% 58% F 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.61% 58% F 74% C
Average Annual (5 Year Horizon)  
Capital Gain 22.48% 100% F 86% B+
Dividend Return 22.48% 100% F 85% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 52.82% 8% B- 18% F
Risk Adjusted Return 42.55% 50% F 67% D+
Market Capitalization 3.40B 43% F 86% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 24.50 92% 27%
Price/Book Ratio 3.62 50% 24%
Price / Cash Flow Ratio 19.06 64% 18%
Price/Free Cash Flow Ratio 15.33 64% 24%
Management Effectiveness  
Return on Equity 14.38% 64% 71%
Return on Invested Capital 8.66% 60% 59%
Return on Assets 5.19% 71% 73%
Debt to Equity Ratio 73.60% 23% 47%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.